Spondyloarthritis

 

Q&A with Dr. Nigil Haroon: COVID-19 and Spondyloarthritis

May 08, 2020

In this Q&A with rheumatologist Nigil Haroon, M.D., Ph.D., of the University Health Network and Krembil Research Institute at the University of Toronto, we discuss COVID-19 factors specific to patients with spondyloarthritis.

Prime-Boost Bests a Single Pneumococcal Vaccination in Patients Receiving DMARDs

March 05, 2020

A two-pronged vaccination approach performs better than a single pneumococcal vaccination in patients receiving conventional DMARDs or abatacept-treated patients, but not in patients receiving rituximab, say researchers writing in Arthritis Research & Therapy.

Methotrexate Lowers Immunogenicity to Adalimumab in Axial Spondyloarthritis

February 29, 2020

Adding methotrexate to adalimumab (Humira, AbbVie) in axial spondyloarthritis was associated with reduced immunogenicity, and prolonged co-medication was associated with long-term maintenance of adalimumab, say researchers recently writing in RMD Open: Rheumatic & Musculoskeletal Diseases.

Personalized Approach Needed for Biologic Tapering

February 07, 2020

The practice of systematically tapering biological disease modifying antirheumatic drugs (bDMARDs) in all patients with inflammatory arthritis who have reached a certain disease activity target may not be supported by current evidence, according to a review published recently in Autoimmunity Reviews

Study Questions BASDAI for Prescribing TNF Inhibitors in Ankylosing Spondylitis

February 07, 2020

The internationally recommended Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cutoff of four and above may not be applicable when initiating treatment with the tumor necrosis factor alpha inhibitor (TNFi) golimumab (Simponi, Janssen), say researchers recently writing in The Journal of Rheumatology.